Inokain drops Ch. 0.4% 5ml vial

Description

Composition
Active substance:
1 ml contains: benoksinata hydrochloride (oxybuprocaine hydrochloride) 4 mg ;.
Excipients:
Benzalkonium chloride 0.1 mg, 19.0 mg of boric acid, disodium edetate 0.1 mg Sodium chloride 8.0 mg Water for injection to 1 ml.
Description:
The clear, colorless solution.
Product form:
0.4% eye drops.
5 ml into a plastic dropper bottle-screw cap. Each vial-IV together with instructions for use placed in a cardboard box.
5 ml in dark glass bottles, closed with a rubber stopper, a crimped aluminum cap with plastic safety cap. In one glass vial with a sterile dropper, packed in a plastic bag and placed in a cardboard box, together with instructions for use.
Contraindications
Individual hypersensitivity to the drug.
Dosage
0.4%
Indications
Local anesthesia in ophthalmology:
measuring intraocular pressure (tonometry); Gonioscopy; diagnostic scraping of the conjunctiva; extracting foreign bodies and sutures from the cornea and conjunctiva; short-term surgical interventions on the cornea and conjunctiva.
Interaction with other drugs
The literature has not described positive or negative effects in the simultaneous administration into conjunctival cavity oxybuprocaine and other conventionally employed ophthalmic drops.
It is noted that oxybuprocaine can theoretically reduce the antibacterial activity of sulfonamides.
Overdose
Data on overdose of the drug available.
pharmachologic effect
Pharmacological group:
Local anesthetic.
Pharmacodynamics:
A local anesthetic; blocks the nerve endings. It penetrates into the tissue at the local appointment. By comparison with tetracaine and other local anesthetics has minimal irritant effect on the conjunctiva and cornea.
Superficial anesthesia conjunctiva and cornea occurs within 30 seconds and lasts 15 minutes.
Pharmacokinetics:
Inokain® easily penetrates into the stroma of the cornea after a single instillation into conjunctival cavity it. Over the next 15 minutes is observed the quantitative decrease stromal drug concentration that causes a 12-15 minute period, anesthesia during a single instillation.
Pregnancy and breast-feeding
Sufficient experience of use of the drug during pregnancy, lactation and children do not have. Inokaina® possible to use for the treatment of children, pregnant and nursing mothers prescribed by a doctor, if the expected therapeutic effect is greater than the risk of possible side effects.
Conditions of supply of pharmacies
On prescription.
side effects
Transient tingling, burning and redness of the conjunctiva; allergic reactions; keratitis (rare).
special instructions
Use only for instillation into the conjunctival sac. Do not use for injection.
Continuous, repeated and prolonged use (and other local anesthetics) can lead to a stable clouding of the cornea.
Not intended for long-term therapy in complex treatment of diseases of the eye.
During anesthesia is necessary to protect the eyes from irritating chemical effects, foreign bodies and friction.
Storage conditions
At temperatures above 25 ° C, protected from light. Do not freeze. Keep out of the reach of children.
Dosing and Administration
Topically instilled into the conjunctival sac of one droplet.
Duration of anesthesia (up to 1 hours) provides a 3-fold instillation at intervals of 4-5 minutes.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist